Propel Bio Management, LLC
13F Reported Value
ⓘ$158.7M
Holdings
38
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Propel Bio Management, LLC disclosed 38 positions worth $158.7M in its Form 13F-HR for Q1 2026, led by $PAGP (PLAINS GP HOLDINGS LP) at 19.0% of the equity portfolio, followed by $ACHV and $PHAT. During the quarter the fund opened 22 new positions and exited 4 — including a new stake in $CORT and a full exit from $NKTR. The portfolio is most concentrated in Healthcare (79.2% of disclosed assets). All figures are sourced directly from Propel Bio Management, LLC’s Form 13F-HR filing with the SEC under CIK 1969764.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 52.9#1,317
Quality
$30.2M1,272,360 sh - —
Quality
$11.4M3,786,425 sh - 32.5#2,264
Quality
$9.4M841,272 sh - 54.9
Quality
$9.2M979,698 sh - 55.4
Quality
$6.0M147,828 sh - 44.3
Quality
$6.0M1,329,899 sh - —
Quality
$5.6M314,543 sh - —
Quality
$5.6M644,421 sh - —
Quality
$5.1M4,118,321 sh - 13.2
Quality
$4.1M131,364 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 PLAINS GP HOLDINGS LP$PAGP | 52.9#1,317 | $30.2M | 1,272,360 |
 ACHIEVE LIFE SCIENCES, INC.$ACHV | — | $11.4M | 3,786,425 |
 Phathom Pharmaceuticals, Inc.$PHAT | 32.5#2,264 | $9.4M | 841,272 |
 DELCATH SYSTEMS, INC.$DCTH | 54.9 | $9.2M | 979,698 |
 CORCEPT THERAPEUTICS INC$CORT | 55.4 | $6.0M | 147,828 |
 ABEONA THERAPEUTICS INC.$ABEO | 44.3 | $6.0M | 1,329,899 |
 Vor Biopharma Inc.$VOR | — | $5.6M | 314,543 |
 Kyverna Therapeutics, Inc.$KYTX | — | $5.6M | 644,421 |
 Milestone Pharmaceuticals Inc.$MIST | — | $5.1M | 4,118,321 |
 Celldex Therapeutics, Inc.$CLDX | 13.2 | $4.1M | 131,364 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Propel Bio Management, LLC's 38 positions.
Showing top 10 of 38 holdings.
Sector Allocation
Healthcare
$125.7M
Energy
$30.2M
Technology
$2.8M
Full Holdings — Propel Bio Management, LLC (Q1 2026)
All 38 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PAGP | PLAINS GP HOLDINGS LP | $30.2M | 19.0% | +0% | 52.9 |
| 2 | $ACHV | ACHIEVE LIFE SCIENCES, INC. | $11.4M | 7.2% | +0% | — |
| 3 | $PHAT | Phathom Pharmaceuticals, Inc. | $9.4M | 5.9% | +14% | 32.5 |
| 4 | $DCTH | DELCATH SYSTEMS, INC. | $9.2M | 5.8% | +123% | 54.9 |
| 5 | $CORT | CORCEPT THERAPEUTICS INC | $6.0M | 3.8% | NEW | 55.4 |
| 6 | $ABEO | ABEONA THERAPEUTICS INC. | $6.0M | 3.8% | +60% | 44.3 |
| 7 | $VOR | Vor Biopharma Inc. | $5.6M | 3.5% | NEW | — |
| 8 | $KYTX | Kyverna Therapeutics, Inc. | $5.6M | 3.5% | -3% | — |
| 9 | $MIST | Milestone Pharmaceuticals Inc. | $5.1M | 3.2% | +0% | — |
| 10 | $CLDX | Celldex Therapeutics, Inc. | $4.1M | 2.6% | -15% | 13.2 |
| 11 |  $CMPS | COMPASS Pathways plc | $4.1M | 2.6% | -14% | — |
| 12 |  $VRDN | Viridian Therapeutics, Inc.\DE | $4.1M | 2.6% | -26% | 30.5 |
| 13 |  $IVA | Inventiva S.A. | $4.0M | 2.5% | -28% | — |
| 14 |  $SABS | SAB Biotherapeutics, Inc. | $3.9M | 2.5% | +55% | — |
| 15 |  $OBIO | Orchestra BioMed Holdings, Inc. | $3.8M | 2.4% | NEW | 8.7 |
| 16 |  $FDMT | 4D Molecular Therapeutics, Inc. | $3.6M | 2.3% | NEW | 23.2 |
| 17 |  $OCS | Oculis Holding AG | $3.3M | 2.1% | -29% | — |
| 18 |  $OCUL | OCULAR THERAPEUTIX, INC | $3.2M | 2.0% | NEW | 12.8 |
| 19 |  $UPB | Upstream Bio, Inc. | $3.1M | 1.9% | NEW | 22.6 |
| 20 |  $AQST | Aquestive Therapeutics, Inc. | $3.0M | 1.9% | NEW | 11.7 |
| 21 |  $EYPT | EyePoint, Inc. | $2.8M | 1.8% | NEW | 10.3 |
| 22 |  $TRVI | Trevi Therapeutics, Inc. | $2.6M | 1.7% | NEW | — |
| 23 |  $ZVRA | ZEVRA THERAPEUTICS, INC. | $2.6M | 1.7% | +343% | 65.6 |
| 24 |  $IMUX | IMMUNIC, INC. | $2.6M | 1.6% | NEW | — |
| 25 |  $CHRS | Coherus Oncology, Inc. | $2.4M | 1.5% | NEW | 42.9 |
| 26 |  $OVID | Ovid Therapeutics Inc. | $2.0M | 1.3% | NEW | 13.1 |
| 27 |  $PALI | PALISADE BIO, INC. | $2.0M | 1.3% | NEW | — |
| 28 |  $KLRS | Kalaris Therapeutics, Inc. | $1.7M | 1.1% | +603% | — |
| 29 |  $QURE | uniQure N.V. | $1.7M | 1.1% | NEW | — |
| 30 |  $LONA | LeonaBio, Inc. | $1.5M | 0.9% | +0% | — |
| 31 |  $NUVB | Nuvation Bio Inc. | $1.4M | 0.9% | NEW | 29.5 |
| 32 |  $MAZE | Maze Therapeutics, Inc. | $1.3M | 0.8% | NEW | 19.7 |
| 33 |  $EVMN | Evommune, Inc. | $1.3M | 0.8% | NEW | — |
| 34 |  $CRVS | Corvus Pharmaceuticals, Inc. | $1.3M | 0.8% | NEW | — |
| 35 |  $ALDX | Aldeyra Therapeutics, Inc. | $1.2M | 0.8% | NEW | — |
| 36 |  $ARTV | Artiva Biotherapeutics, Inc. | $949,818 | 0.6% | NEW | — |
| 37 |  $CNTB | Connect Biopharma Holdings Ltd | $553,909 | 0.3% | NEW | — |
| 38 |  $MSLE | Satellos Bioscience Inc. | $57,116 | 0.0% | NEW | — |
New Positions (22)
$CORT CORCEPT THERAPEUTICS INC$6.0M$VOR Vor Biopharma Inc.$5.6M$OBIO Orchestra BioMed Holdings, Inc.$3.8M$FDMT 4D Molecular Therapeutics, Inc.$3.6M$OCUL OCULAR THERAPEUTIX, INC$3.2M$UPB Upstream Bio, Inc.$3.1M$AQST Aquestive Therapeutics, Inc.$3.0M$EYPT EyePoint, Inc.$2.8M$TRVI Trevi Therapeutics, Inc.$2.6M$IMUX IMMUNIC, INC.$2.6M$CHRS Coherus Oncology, Inc.$2.4M$OVID Ovid Therapeutics Inc.$2.0M$PALI PALISADE BIO, INC.$2.0M$QURE uniQure N.V.$1.7M$NUVB Nuvation Bio Inc.$1.4M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Propel Bio Management, LLC including:
Track Propel Bio Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Propel Bio Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Propel Bio Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Propel Bio Management, LLC (SEC CIK: 1969764), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Propel Bio Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.